Bolt Biotherapeutics (BOLT) Competitors

Bolt Biotherapeutics (NASDAQ:BOLT) and Curis (NASDAQ:CRIS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Do institutionals and insiders hold more shares of BOLT or CRIS?

86.7% of Bolt Biotherapeutics shares are owned by institutional investors. Comparatively, 30.0% of Curis shares are owned by institutional investors. 6.1% of Bolt Biotherapeutics shares are owned by insiders. Comparatively, 5.7% of Curis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media prefer BOLT or CRIS?

In the previous week, Curis had 2 more articles in the media than Bolt Biotherapeutics. MarketBeat recorded 6 mentions for Curis and 4 mentions for Bolt Biotherapeutics. Bolt Biotherapeutics' average media sentiment score of 0.67 beat Curis' score of 0.56 indicating that Bolt Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bolt Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Curis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is BOLT or CRIS more profitable?

Curis has a net margin of -443.35% compared to Bolt Biotherapeutics' net margin of -665.56%. Bolt Biotherapeutics' return on equity of -69.46% beat Curis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bolt Biotherapeutics	-665.56%	-69.46%	-48.55%
Curis	-443.35%	-923.37%	-78.35%

Do analysts prefer BOLT or CRIS?

Bolt Biotherapeutics presently has a consensus target price of $2.50, indicating a potential upside of 669.23%. Curis has a consensus target price of $17.00, indicating a potential upside of 754.27%. Given Curis' stronger consensus rating and higher possible upside, analysts plainly believe Curis is more favorable than Bolt Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bolt Biotherapeutics	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.33
Curis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility and risk, BOLT or CRIS?

Bolt Biotherapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, Curis has a beta of 3.65, suggesting that its share price is 265% more volatile than the S&P 500.

Does the MarketBeat Community prefer BOLT or CRIS?

Curis received 614 more outperform votes than Bolt Biotherapeutics when rated by MarketBeat users. Likewise, 67.28% of users gave Curis an outperform vote while only 63.28% of users gave Bolt Biotherapeutics an outperform vote.

Company	Underperform	Outperform
Bolt Biotherapeutics	Outperform Votes 81 63.28%	Underperform Votes 47 36.72%
Curis	Outperform Votes 695 67.28%	Underperform Votes 338 32.72%

Which has higher earnings and valuation, BOLT or CRIS?

Curis has higher revenue and earnings than Bolt Biotherapeutics. Curis is trading at a lower price-to-earnings ratio than Bolt Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bolt Biotherapeutics	$3.64M	3.43	-$69.20M	-$1.67	-0.19
Curis	$11.20M	1.86	-$47.41M	-$6.23	-0.32

Summary

Curis beats Bolt Biotherapeutics on 9 of the 17 factors compared between the two stocks.